×
About 78 results

ALLMedicine™ Acute Myeloblastic Leukemia Center

Research & Reviews  26 results

Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and R...
https://doi.org/10.1097/MPH.0000000000002225
Journal of Pediatric Hematology/oncology; Aylan Gelen S, Sarper N et. al.

Jun 1st, 2021 - Indications of leukapheresis (LPh) and the prophylactic use of rasburicase in tumor lysis syndrome (TLS) of patients with acute leukemia with hyperleukocytosis are not clear. In this retrospective single-center pediatric study, the outcomes of pat...

Biomarkers involved in evaluation of platelets function in South-Eastern Romanian patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137019
Medicine Matei E, Aschie M et. al.

May 21st, 2021 - At present, various researches presented how subtypes of hematological malignancies are related to stages of the immune response, because the activated immune system represents a promising form in cancer treatment. This study explores the relation...

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide ...
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.

Dec 30th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...

Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a p...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.

May 21st, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...

Changes in long term survival after diagnosis with common hematologic malignancies in t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083
Blood Cancer Journal; Pulte D, Jansen L et. al.

May 15th, 2020 - Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (...

see more →

Clinicaltrials.gov  5 results

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
https://clinicaltrials.gov/ct2/show/NCT01296178

Apr 9th, 2020 - Primary objectives Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival...

A Study for Patients With Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT01214655

May 13th, 2019 - This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukem...

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
https://clinicaltrials.gov/ct2/show/NCT02473146

Jul 26th, 2018 - Purpose : The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition with standard doses of Ara-C in previously untreated patients aged...

Prospective Database for Acute Myeloblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT00538278

Dec 13th, 2011 - Prospective Database for Acute Myeloblastic Leukemia

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT00487448

Nov 19th, 2008 - To reach the first remission, the patients receive one cycle of FLAG-IDA combination, that include: Fludarabine 30 mg/m 2 /d Days 1 to 4 in IV perfusion during 30 minutes; Cytarabine 2 g/m 2/d, days 1 to 4 in IV perfusion during 4 hours glycosylat...

see more →